|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM063438232 |
| 003 |
DE-627 |
| 005 |
20231221223715.0 |
| 007 |
tu |
| 008 |
231221s1983 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0212.xml
|
| 035 |
|
|
|a (DE-627)NLM063438232
|
| 035 |
|
|
|a (NLM)6366806
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jaffé, G
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clenbuterol and salbutamol in the symptomatic treatment of patients with reversible airways obstruction
|
| 264 |
|
1 |
|c 1983
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.03.1984
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a In a single-blind, partially randomized, crossover study, 48 patients with reversible airways obstruction were treated with 4 mg salbutamol 3-times daily, 20 micrograms clenbuterol twice daily and 40 micrograms clenbuterol twice daily, each regimen being given for 2 weeks. With all treatments there was an improvement in lung function, as indicated by daily monitoring of PEFR and subjective assessment of breathing, and there were no significant differences between them. Side-effects were few. It is considered, therefore, that twice daily regimens of clenbuterol can be as effective as salbutamol given 3-times daily and this may help to improve patient compliance
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Ethanolamines
|2 NLM
|
| 650 |
|
7 |
|a Albuterol
|2 NLM
|
| 650 |
|
7 |
|a QF8SVZ843E
|2 NLM
|
| 650 |
|
7 |
|a Clenbuterol
|2 NLM
|
| 650 |
|
7 |
|a XTZ6AXU7KN
|2 NLM
|
| 700 |
1 |
|
|a Grimshaw, J J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 3(1983), 7 vom: 15., Seite 492-5
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:3
|g year:1983
|g number:7
|g day:15
|g pages:492-5
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 3
|j 1983
|e 7
|b 15
|h 492-5
|